Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Uveal Melanoma
NCT02359851Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2015
- Primary completion
- May 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Uveal melanoma (UM), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Objective Response Rate at 3 years. Started May 2015; status: terminated.
02
Drugs
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02359851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359851.